Clinical resistance to imatinib: mechanisms and implications.

Andreas Hochhaus, Timothy Hughes

Journal: Hematology/oncology clinics of North America 2004;18(3):641-56, ix

PMID: 15271397

Full Text on Elsevier Science View on PubMed

Abstract

Although responses to imatinib in chronic phase chronic myelogenous leukemia have been durable in most cases, most patients in advanced disease develop resistance and relapse after a short duration of therapy. The mechanisms of drug resistance are diverse, but in most cases, mutations are found at the time of resistance that change amino acids within the kinase domain of BCR-ABL. Cytogenetic and molecular analyses at the time of resistance are suggested to guide therapy.

Address: III. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg, Wiesbadener Strasse 7-11, 68305 Mannheim, Germany. [email protected]

DOI: 10.1016/j.hoc.2004.03.001

Link outs

Free resources

Medical:

https://medlineplus.gov/chronicmyeloidleukemia.htm...

Miscellaneous:

https://assays.cancer.gov/CPTAC-1776

Subscription / membership required

Full Text Sources:

MeSH Terms: Benzamides, Drug Resistance, Neoplasm, Fusion Proteins, bcr-abl, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mutation, Piperazines, Pyrimidines